ID: h-f7db2634ee
Hypothesis
LXR Agonism (H4): Microglial Lipid Efflux Promotion
GW3965-mediated LXR activation promotes cholesterol efflux via ABCA1/ABCG1, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
GW3965-mediated LXR activation promotes cholesterol efflux via ABCA1/ABCG1, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation. Amplifies compensatory anti-inflammatory response. Significant systemic toxicity concerns (hepatic steatosis, hypertriglyceridemia) and isoform non-selectivity limit translational potential.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Target Gene: NR1H3 LXR/NR1H3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Contradicts
GW3965 induces hepatic steatosis and hypertriglyceridemia via SREBP1c activation
Contradicts
GW3965 activates both LXRα and LXRβ; non-selective activation increases systemic toxicity
Contradicts
LXR agonism does not reduce neuronal lipid secretion; microglia must continuously handle same load
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NR1H3
No curated PDB or AlphaFold mapping for NR1H3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NR1H3 (LXRα/NR1H3) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NR1H3 (LXRα.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.2%
Volatility
Low
0.0057
Events (7d)
2
Price History
▼6.1%💾 Resource Usage
LLM Tokens
11,236
$0.0337
Total Cost
$0.0337
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6J mice with established tau pathology (PS19 model) receive daily intraperitoneal GW3965 (10 mg/kg) for 4 weeks, THEN microglial ABCA1/ABCG1 expression will increase ≥2-fold in isolated CD11b | Microglial ABCA1/ABCG1 expression increases ≥2-fold; hippocampal extracellular cholesterol (assessed by LDL receptor expression as proxy) rises by ≥30% indicati | — no observation — | pending | 0.65 |
| IF female 5xFAD mice receive oral GW3965 (15 mg/kg BID) for 8 weeks, THEN hippocampal IBA1+ microglial coverage of amyloid plaques will increase ≥40% and plasma TNF-α will decrease ≥50%, WHILE hepatic | Enhanced microglial peri-plaque coverage (indicating improved lipid handling capacity) and reduced systemic inflammation, but with hepatotoxicity evidenced by h | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF C57BL/6J mice with established tau pathology (PS19 model) receive daily intraperitoneal GW3965 (10 mg/kg) for 4 weeks, THEN microglial ABCA1/ABCG1 expression will increase ≥2-fold in isolated CD11b+ cells and hippocampal cholesterol efflux will be elevated compared to vehicle-treated controls wit
Predicted outcome: Microglial ABCA1/ABCG1 expression increases ≥2-fold; hippocampal extracellular cholesterol (assessed by LDL receptor expression as proxy) rises by ≥30
Falsification: No significant change in microglial ABCA1/ABCG1 mRNA/protein (fold change <1.5) or no elevation in cholesterol efflux markers in the GW3965 group versus vehicle after 4 weeks of treatment.
pendingconf 55%
IF female 5xFAD mice receive oral GW3965 (15 mg/kg BID) for 8 weeks, THEN hippocampal IBA1+ microglial coverage of amyloid plaques will increase ≥40% and plasma TNF-α will decrease ≥50%, WHILE hepatic triglyceride content will increase ≥2-fold compared to vehicle-treated 5xFAD mice within 10 weeks o
Predicted outcome: Enhanced microglial peri-plaque coverage (indicating improved lipid handling capacity) and reduced systemic inflammation, but with hepatotoxicity evid
Falsification: If microglial peri-plaque coverage does not increase (≤20% change) or if plasma TNF-α does not decrease despite ABCA1/ABCG1 upregulation, the anti-inflammatory lipid efflux mechanism is not supported.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.